Trials / Completed
CompletedNCT03801928
Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease
OBSERVATIONAL, REAL WORLD STUDY OF INFLECTRA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD) IN THE UNITED STATES AND CANADA
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 118 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, observational, multicenter study conducted in adult patients with ulcerative colitis (UC) or Crohn's disease (CD). The study plans to recruit 300 subjects in the United States and Canada in which the participating physician has decided to treat with INFLECTRA. The study will evaluate treatment patterns, adherence, disease activity, remission status, relapse status, treatment satisfaction, and healthcare resource utilization. Patient outcomes will be assessed at four time points (quarterly) for approximately 52 weeks after the decision to initiate treatment with INFLECTRA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Inflectra | The study plans to recruit 300 subjects in the United States and Canada initiating or switching to treatment with INFLECTRA over an 8 month period. The decision to start INFLECTRA will be entirely a clinical decision made by the participating physician irrespective of this study. |
Timeline
- Start date
- 2018-02-23
- Primary completion
- 2020-02-07
- Completion
- 2020-02-07
- First posted
- 2019-01-14
- Last updated
- 2021-03-02
- Results posted
- 2021-03-02
Locations
15 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT03801928. Inclusion in this directory is not an endorsement.